We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug
Read MoreHide Full Article
Panbela Therapeutics (PBLA - Free Report) , a clinical-stage biopharmaceutical company, gained almost 29.3% on Apr 12 after the company announced that it enrolled the first patient in phase II clinical study to evaluate CPP-1X-T (Eflornithine tablets) for recent-onset type 1 diabetes.
The study is titled "TArgeting Type 1 Diabetes Using POLyamines (TADPOL)” and is a double-blind, placebo-controlled study that will evaluate the efficacy of CPP-1X-T in patients with recent-onset type 1 diabetes at approximately six academic medical centers in the United States. It aims to assess the effectiveness of CPP-1X-T in improving beta cell function, targeting the beta cell directly via effects on the immune system.
The TADPOL study is led by the Indiana University School of Medicine researchers and funded by the Juvenile Diabetes Research Foundation (JDRF).
Shares of Panbela have plunged 99.2% in the past year compared with the industry's 15% decline.
Image Source: Zacks Investment Research
In the United States, 1.45 million people live with type 1 diabetes, with $16 billion in T1D-associated healthcare expenditure and lost income annually. The potential success of CPP-1X-T in clinical studies could provide significant relief to this patient population and reduce healthcare expenditures.
Panbela’s surge was also due to the recently regained rights to develop and commercialize Flynpovi — a combination of CPP-1X (eflornithine) and sulindac to treat patients with familial adenomatous polyposis (FAP) — in North America.
The company's pipeline includes assets in clinical trials for FAP, pancreatic cancer, colorectal cancer prevention and ovarian cancer. Panbela is committed to bringing innovative treatments for urgent unmet medical needs and Flynpovi has the potential to make a meaningful difference for FAP patients globally. PBLA's lead candidates include Ivospemin (SBP-101) and Flynpovi.
Loss per share estimates for CRISPR have narrowed from $8.21 to $7.35 for 2023 in the past 60 days.
The company's earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, the average surprise being 3.19%. CRSP's shares have plunged 30.1% in the past year
Loss per share estimates for Kala have narrowed from $18.34 to $16.54 for 2023 and from $14.41 to $13.12 for 2024 in the past 60 days. The company's shares have plunged 59% in the past year.
KALA's earnings beat estimates in two of the last four quarters and missed the mark in the other two, the average surprise being 11.56%.
Loss per share estimates for Allogene Therapeutics have narrowed from $2.83 to $2.44 for 2023 and from $2.69 to $2.46 for 2024 in the past 60 days.
The company's earnings beat estimates in each of the trailing four quarters, the average surprise being 8.33%. ALLO's shares have plunged 44.4% in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug
Panbela Therapeutics (PBLA - Free Report) , a clinical-stage biopharmaceutical company, gained almost 29.3% on Apr 12 after the company announced that it enrolled the first patient in phase II clinical study to evaluate CPP-1X-T (Eflornithine tablets) for recent-onset type 1 diabetes.
The study is titled "TArgeting Type 1 Diabetes Using POLyamines (TADPOL)” and is a double-blind, placebo-controlled study that will evaluate the efficacy of CPP-1X-T in patients with recent-onset type 1 diabetes at approximately six academic medical centers in the United States. It aims to assess the effectiveness of CPP-1X-T in improving beta cell function, targeting the beta cell directly via effects on the immune system.
The TADPOL study is led by the Indiana University School of Medicine researchers and funded by the Juvenile Diabetes Research Foundation (JDRF).
Shares of Panbela have plunged 99.2% in the past year compared with the industry's 15% decline.
Image Source: Zacks Investment Research
In the United States, 1.45 million people live with type 1 diabetes, with $16 billion in T1D-associated healthcare expenditure and lost income annually. The potential success of CPP-1X-T in clinical studies could provide significant relief to this patient population and reduce healthcare expenditures.
Panbela’s surge was also due to the recently regained rights to develop and commercialize Flynpovi — a combination of CPP-1X (eflornithine) and sulindac to treat patients with familial adenomatous polyposis (FAP) — in North America.
The company's pipeline includes assets in clinical trials for FAP, pancreatic cancer, colorectal cancer prevention and ovarian cancer. Panbela is committed to bringing innovative treatments for urgent unmet medical needs and Flynpovi has the potential to make a meaningful difference for FAP patients globally. PBLA's lead candidates include Ivospemin (SBP-101) and Flynpovi.
Panbela Therapeutics Inc. Price and Consensus
Panbela Therapeutics Inc. price-consensus-chart | Panbela Therapeutics Inc. Quote
Zacks Rank & Stocks to Consider
Panbela currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks for investors interested in the same sector are CRISPR Therapeutics (CRSP - Free Report) , Kala Pharmaceuticals (KALA - Free Report) and Allogene Therapeutics (ALLO - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Loss per share estimates for CRISPR have narrowed from $8.21 to $7.35 for 2023 in the past 60 days.
The company's earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, the average surprise being 3.19%. CRSP's shares have plunged 30.1% in the past year
Loss per share estimates for Kala have narrowed from $18.34 to $16.54 for 2023 and from $14.41 to $13.12 for 2024 in the past 60 days. The company's shares have plunged 59% in the past year.
KALA's earnings beat estimates in two of the last four quarters and missed the mark in the other two, the average surprise being 11.56%.
Loss per share estimates for Allogene Therapeutics have narrowed from $2.83 to $2.44 for 2023 and from $2.69 to $2.46 for 2024 in the past 60 days.
The company's earnings beat estimates in each of the trailing four quarters, the average surprise being 8.33%. ALLO's shares have plunged 44.4% in the past year.